Real-World Evidence Should Be Flagged In US Drug And Biologic Applications
Executive Summary
FDA will track RWE submissions under INDs, NDAs or BLAs and wants sponsors to use a simple, uniform format to identify real-world data sources and evidence generated from that data in such filings.
You may also be interested in...
Digital Health Technologies: Use In Clinical Studies Comes With Practical Challenges
Whether subjects can use their own personal devices, how to manage mid-study technology updates, and the extent to which data gathered will be shared with patients in real-time are all issues that sponsors, investigators and regulators need to consider.
Digital Health Technologies In Clinical Studies Comes With Practical Challenges
Whether subjects can use their own personal devices, how to manage mid-study technology updates, and the extent to which data gathered will be shared with patients in real-time are all issues that sponsors, investigators and regulators need to consider.
Real-World Evidence More Helpful To US FDA In Cases Of High Clinical Trial Efficacy
Pfizer-funded systematic review of approved oncology applications that contained RWE highlights common deficiencies flagged by FDA and says strength of trial data is a key determinant of the extent to which RWE is needed and considered by the agency.